Atlas FDA

Alinity m HCV

FDA premarket approval P190025/S002 · decided 2020-06-09

Approval details

PMA number
P190025
Supplement
S002
Supplement type
30-Day Notice
Supplement reason
Process Change - Manufacturer/Sterilizer/Packager/Supplier
Trade name
Alinity m HCV
Generic name
Assay, hybridization and/or nucleic acid amplification for detection of hepatitis c rna,hepatitis c virus
Applicant
Abbott Molecular, Inc.
Date received
2020-05-07
Decision date
2020-06-09
Days to decision
33 days
Decision code
OK30
Product code
MZP
Advisory committee
Microbiology
Expedited review
No
Location
Des Plaines, IL
Statement
Manufacturing change to increase the fill volume of Activation Reagent in the Alinity m HCV ACT TRAY 2.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
Alinity m HCV (K252102)Abbott Molecular, Inc.2025-09-25
Alinity m EBV (09N43-095) (K243489)Abbott Molecular, Inc.2025-07-28
Alinity m CMV (K243485)Abbott Molecular, Inc.2025-07-01
Alinity m BKV (K241921)Abbott Molecular, Inc.2025-03-24
Alinity m Resp-4-Plex (K241573)Abbott Molecular, Inc.2025-02-14
Alinity m HSV 1 & 2 / VZV (K233349)Abbott Molecular, Inc.2024-05-03
Alinity m STI Assay (K222379)Abbott Molecular, Inc.2023-03-03
Alinity m EBV AMP Kit (List No. 09N43-095), Alinity m EBV CTRL Kit (List No. 09N43-085), Alinity m EBV CAL Kit (List No. 09N43-075) (K212778)Abbott Molecular, Inc.2022-07-15